companydata.dkAdaptVac ApS: Financial statements 2023
CVR: 38732730
AdaptVac ApS (CVR 38732730) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 69,205,437 and a net result of DKK 50,885,920 compared with DKK -4,794,662 the year before. Equity amounted to DKK 58,648,012. The solvency ratio was 59.7%. The company had 6 employees in the financial year.
- Gross Profit
- 69,205,437 kr.
- Profit/Loss
- 50,885,920 kr.
- Equity
- 58,648,012 kr.
- Total Assets
- 98,166,874 kr.
- Employees
- 6
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 69.2 mio. | 50.9 mio. | 58.6 mio. | 6 |
| 2022 | - | -1.6 mio. | -4.8 mio. | 7.8 mio. | 6 |
| 2021 | - | 1.3 mio. | -1.8 mio. | 12.6 mio. | 5 |
| 2020 | - | 20.2 mio. | 15.5 mio. | 15.3 mio. | 3 |
| 2019 | - | 1.4 mio. | -185 t. | -122 t. | 3 |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
AdaptVac ApS has published its annual report for 2022. Gross profit came to DKK -1,581,922, and the net result was DKK -4,794,662.
About AdaptVac ApS
AdaptVac ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Willem Adriaan De Jongh and Adam Frederik Sander Bertelsen. The company is owned by EXPRES2ION BIOTECHNOLOGIES ApS and NextGen Vaccines Holding ApS. In 2025, the company reported a gross profit of DKK -3,160,505 and a net result of DKK -7,053,665 compared with DKK 1,714,349 the year before. Equity amounted to DKK 10,808,696.